Reference: UK Health Security Agency. (2023). Estimation of number needed to vaccinate to prevent a COVID-19 hospitalisation for primary vaccination, booster vaccination (3rd dose), autumn 2022 and spring 2023 booster for those newly in a risk group. Retrieved from [URL] Summary: The UK Health Security Agency’s report outlines the calculation of the number needed to […]
Reference: Morens, D. M., Taubenberger, J. K., & Fauci, A. S. (2023). Rethinking next-generation vaccines for coronaviruses, influenza viruses, and other respiratory viruses. Cell Host & Microbe, 31, 146-157. https://doi.org/10.1016/j.chom.2022.11.016 Summary: The article discusses the challenges in developing effective vaccines for respiratory viruses such as SARS-CoV-2 and influenza. These viruses often replicate rapidly in the
Reference: Morens, D. M., Taubenberger, J. K., & Fauci, A. S. (2023). Rethinking next-generation vaccines for coronaviruses, influenza viruses, and other respiratory viruses. Cell Host & Microbe, 31, 146–157. https://doi.org/10.1016/j.chom.2022.11.016 Summary: The authors discuss the challenges in developing effective vaccines for respiratory viruses like influenza and SARS-CoV-2. They highlight that these viruses replicate rapidly in
Reference: Yonker, L. M., Swank, Z., Bartsch, Y. C., et al. (2023). Circulating spike protein detected in post–COVID-19 mRNA vaccine myocarditis. Circulation, 147, xxx–xxx. https://doi.org/10.1161/CIRCULATIONAHA.122.061025 Summary: This study investigates the immunological profiles of adolescents and young adults who developed myocarditis following mRNA COVID-19 vaccination. The research involved blood sampling from 16 patients hospitalised with myocarditis
Reference: Kirsch, S. (2023). What you need to know about COVID vaccine safety. COVID-19 Early Treatment Fund. Retrieved from [insert URL] Summary: In his article, Steve Kirsch argues that COVID vaccines may be more harmful than beneficial, suggesting that for every life saved by vaccination, two people may die due to vaccine-related complications, creating a
Reference: Krauson, A. J., Casimero, F. V. C., Siddiquee, Z., & Stone, J. R. (2023). Duration of SARS-CoV-2 mRNA vaccine persistence and factors associated with cardiac involvement in recently vaccinated patients. npj Vaccines, 8, 141. https://doi.org/10.1038/s41541-023-00742-7 Summary: This study investigates the persistence of SARS-CoV-2 mRNA vaccines in human tissues, focusing on recently vaccinated patients. Autopsies
Reference: Pfizer. (2023). NCT04368728 FDA Clinical Trial: C4591001. Retrieved from [link to the document] Summary: The clinical trial NCT04368728, with protocol number C4591001, aims to evaluate the safety, tolerability, immunogenicity, and efficacy of RNA vaccine candidates against COVID-19 in healthy individuals. The trial is structured in three phases, assessing different doses and age groups, with